Oragenics, Inc. shared its Q2 2025 shareholder update on August 11, 2025, highlighting strategic and financial milestones. The company reported a net loss of $4.33 million for the six months ended June 30, 2025, a decrease from $5.51 million for the same period in 2024.
As of June 30, 2025, Oragenics held cash and cash equivalents of $18.0 million, reflecting a strengthened financial foundation. Research and development expenses for the six months ended June 30, 2025, were $0.7 million, down from $1.3 million in the prior year.
General and administrative expenses also saw a reduction, totaling $3.3 million for the six months ended June 30, 2025, compared to $3.6 million in 2024. These financial improvements are expected to support the acceleration of the ONP-002 program and other development activities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.